Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE)

 Gaucher Disease / Posted 2 months ago

Brief Summary
J3Z-MC-OJAB is an open-label, Phase 1/2, multicenter study to evaluate the safety and efficacy of single-dose LY3884961 (formerly PR001) in infants diagnosed with Type 2 Gaucher disease (GD2). For each patient, the study will be approximately 5 years in duration. During the first 12 months after dosing, patients will be evaluated for the effects of LY3884961 on safety, tolerability, immunogenicity, biomarkers, and efficacy. Patients will be followed up for an additional 4 years to monitor safety and changes on selected biomarkers and clinical outcomes.
  • Inclusion Criteria :
    • Bi-allelic GBA1 mutations consistent with a diagnosis of GD2 confirmed by the central laboratory.
    • Clinical diagnosis of GD2
    • Parent/legal guardian has the ability to understand the purpose and risks of the study and provide written informed consent and authorization to use protected health information in accordance with national and local privacy regulations.
    • Patient has a reliable informant (i.e., parent/legal guardian) willing and able to participate in the study as a source of information on the patient's health status and cognitive and functional abilities (including providing input into the rating scales).
  • Exclusion Criteria :
    • Diagnosis of a significant CNS disease other than GD2 that may be a cause for the patient's GD symptoms or may confound study objectives.
    • Achieved independent gait.
    • Severe peripheral symptoms of GD which, in the opinion of the Investigator, would pose an unacceptable risk to the patient or interfere with the patient's ability to comply with study procedures or interfere with the conduct of the study.
    • Concomitant disease, condition, or treatment which, in the opinion of the Investigator, would pose an unacceptable risk to the patient or interfere with the patient's ability to comply with study procedures or interfere with the conduct of the study.
    • Use of any GD treatment-related substrate reduction therapy.
    • Use of strong inhibitors or inducers of cytochrome P450 3A4 (CYP3A4) or P-glycoprotein (P-gp) medications, herbals, or over-the-counter agents.
    • Any type of prior gene or cell therapy.
    • Live vaccine Immunizations within 4 weeks, or non-live vaccines within 2 weeks prior to the start of required immunosuppressive regimen.
    • Use of blood thinners. Antiplatelet therapies are acceptable if the patient is medically able to temporarily stop them from 7 days prior to dosing and through at least 48 hours after the intracisternal injection and lumbar puncture.
    • Use of systemic immunosuppressant or corticosteroid therapy other than protocol-specified (topical or inhaled preparations for dermatological conditions or asthma are allowed).
    • Participation in another investigational drug or device study within the past 3 months.
    • Brain MRI (magnetic resonance imaging) and MRA (magnetic resonance angiography) showing clinically significant abnormality deemed a contraindication to intracisternal injection.
    • Clinically significant laboratory test result abnormalities assessed at screening.
    • Contraindications or intolerance to radiographic visualization methods (e.g. MRI, MRA, CT), and intolerance to contrast agents used for MRI or CT scans.
    • Contraindications to general anesthesia or sedation.
    • Other protocol-defined inclusion/exclusion criteria may apply.
  • Study end date : September 2028
  • Wales-Based Study Contact : Please speak to your clinician
  • Principal Investigator : Sarah Neuhaus, D.O. (Prevail Therapeutics)
Contact details

Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester,England,M13 9WL  Show Phone Number laura.crowther@mft.nhs.ukStMarysHospitalManchester www.mangen.co.uk

No post found